Similarly, different clinical trials confirmed the beneficial effects of the combination of trastuzumab and pertuzumab plus chemotherapy in the (neo)adjuvant setting [11,12], clearly defining the crucial role of pertuzumab in HER2-positive high-risk early BC. This evidence concerns the gene ERBB2 and breast cancer.